Race and Survival in Unrelated Hematopoietic Cell Transplantation.
Ancestry
HLA
Hematopoietic cell transplantation
Race
Unrelated donor
Journal
Transplantation and cellular therapy
ISSN: 2666-6367
Titre abrégé: Transplant Cell Ther
Pays: United States
ID NLM: 101774629
Informations de publication
Date de publication:
07 2022
07 2022
Historique:
received:
02
12
2021
revised:
14
02
2022
accepted:
30
03
2022
pubmed:
12
4
2022
medline:
7
7
2022
entrez:
11
4
2022
Statut:
ppublish
Résumé
Survival after hematopoietic cell transplantation depends on race/ethnicity and histocompatibility (HLA) between the patient and transplant donor. HLA sequence variation is a genetic construct of continental populations, but its role in accounting for racial disparities of transplant outcome is unknown. To determine disparities in transplant survivorship among patients of diverse race while accounting for patient and donor HLA variation. A total of 26,945 self-described Japanese, U.S. Asian, White, Hispanic, and Black patients received an unrelated donor transplant for the treatment of a life-threatening blood disorder. The risk of mortality with and without adjustment for known HLA risk factors (number and location of donor mismatches; patient HLA-B leader genotype and HLA-DRβ peptide-binding motif) was studied using multivariable models. Survival after HLA-matched transplantation for patients with optimal leader and peptide-binding features was estimated for each race, as was the improvement in survival over calendar-year time by considering year of transplantation as a continuous linear variable. The number, location, and nature of donor HLA mismatches and the frequency of patient HLA-B and HLA-DRB1 sequence motifs differed by race. Japanese patients had superior survival compared to other races without consideration of HLA. After HLA adjustment, three mortality risk strata were identified: Japanese and U.S. Asian (low-risk); White and Hispanic (intermediate-risk), and Black patients (high-risk). Survival for patients with optimal donor and HLA characteristics was superior for Japanese, intermediate for U.S. Asian, White, and Hispanic, and lowest for Black patients. Five-year increments of transplant year were associated with greater decreases in mortality hazards for Black and Hispanic patients than for Japanese, U.S. Asian and White patients. Transplant survivorship disparities are influenced by HLA as a genetic construct of race. A more complete understanding of the factors that influence transplant outcomes provides opportunities to narrow disparities for future patients.
Identifiants
pubmed: 35405366
pii: S2666-6367(22)01193-9
doi: 10.1016/j.jtct.2022.03.026
pmc: PMC9387555
mid: NIHMS1799097
pii:
doi:
Substances chimiques
HLA Antigens
0
Peptides
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
357.e1-357.e6Subventions
Organisme : NHLBI NIH HHS
ID : U10 HL069294
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA231838
Pays : United States
Organisme : NCI NIH HHS
ID : U24 CA076518
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI069197
Pays : United States
Organisme : NHLBI NIH HHS
ID : U01 HL069294
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA100019
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA218285
Pays : United States
Organisme : NCI NIH HHS
ID : P01 CA018029
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA015704
Pays : United States
Informations de copyright
Copyright © 2022 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights reserved.
Références
Blood. 2016 Jan 14;127(2):260-7
pubmed: 26527675
Bone Marrow Transplant. 2015 Jun;50(6):834-9
pubmed: 25798671
Hum Immunol. 2019 Jan;80(1):67-78
pubmed: 30321633
Blood Adv. 2022 Jan 11;6(1):270-280
pubmed: 34529780
Proc Natl Acad Sci U S A. 2013 Oct 8;110(41):16574-9
pubmed: 24062448
Biol Blood Marrow Transplant. 2016 Jan;22(1):23-6
pubmed: 26551633
PLoS One. 2015 Aug 19;10(8):e0135960
pubmed: 26287376
Transplant Proc. 1993 Feb;25(1 Pt 1):159-61
pubmed: 8438260
Hum Genomics. 2015 Jan 07;9:1
pubmed: 25563503
Lancet Haematol. 2020 Jan;7(1):e50-e60
pubmed: 31669248
J Clin Oncol. 2018 Aug 20;36(24):2524-2531
pubmed: 29902106
Hum Immunol. 2013 Oct;74(10):1313-20
pubmed: 23806270
Biol Blood Marrow Transplant. 2005 Mar;11(3):231-9
pubmed: 15744242
Biol Blood Marrow Transplant. 2013 Aug;19(8):1197-203
pubmed: 23747601
Lancet. 2020 May 30;395(10238):1673-1676
pubmed: 32401716
Blood. 2015 Feb 12;125(7):1189-97
pubmed: 25519752
Am J Hum Genet. 2015 Jan 8;96(1):37-53
pubmed: 25529636
Nature. 1999 Oct 28;401(6756):921-3
pubmed: 10553908
NCHS Data Brief. 2019 Jul;(342):1-8
pubmed: 31442191
Blood. 2020 Jul 16;136(3):362-369
pubmed: 32483623
Sci Transl Med. 2012 Jul 25;4(144):144ra101
pubmed: 22837536
Biol Blood Marrow Transplant. 2009 Dec;15(12):1543-54
pubmed: 19896078
Genetics. 2006 Aug;173(4):2121-42
pubmed: 16702436
Best Pract Res Clin Haematol. 2008 Jun;21(2):149-64
pubmed: 18503983
Blood. 2005 Feb 15;105(4):1408-16
pubmed: 15486071
Blood Adv. 2019 Apr 9;3(7):939-944
pubmed: 30917950
Ann N Y Acad Sci. 1995 Dec 29;770:227-36
pubmed: 8597363
Bone Marrow Transplant. 2016 Jun;51(6):778-85
pubmed: 26901703
Blood. 2010 Jun 10;115(23):4664-70
pubmed: 20335219
Bone Marrow Transplant. 2012 Nov;47(11):1385-90
pubmed: 22056642
N Engl J Med. 2014 Jul 24;371(4):339-48
pubmed: 25054717
Transplantation. 1986 Jun;41(6):713-6
pubmed: 3520987